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Abstract 
Glioma is a common type of primary brain tumor that represents 28% of all brain tumors and 80% 
of malignant tumors. According to a recent study by the Centers for Disease Control and 
Prevention (CDC), gliomas account for 53%, 35% and 29% of all brain tumors (68%, 74% and 
81% of malignant brain tumors) among children (aged 0-14), teenagers (aged 15-19) and young 
adults, respectively. Gliomas are often diagnosed through radiological imaging and 
histopathology. There are two main groups of gliomas following World Health Organization’s 
classification: Low grade gliomas (LGG), or grade I and II gliomas; and high grade gliomas 
(HGG), or Grade III and IV gliomas. This study focuses mainly on LGG due to its long term risks, 
such as recurrences and malignant transformations. Although the 5-year mortality rate for LGG 
patients is relatively high (17.6%), several studies reported that the average 5-year recurrence rate 
is up to 55%. However, there is currently limited guidelines for post-treatment management for 
LGG patients. This research aims to estimate the recurrence, malignancy transformation, and 
mortality risks for LGG patients who have had an initial treatment in order to have a better 
understanding of disease progression. These risk estimates can be incorporated in the development 
of a natural history model that can then be used in evaluating and optimizing post-treatment 
management strategies for LGG patients in future research.  
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 Background and Motivation 
The number of brain tumor cases has increased about 140% in the U.S. and Europe between 1979 
and 2003 (Lorenzi, 2003). Gliomas, a type of primary brain tumor, arise from glial cells. The 
etiology of gliomas still remains unknown. Every year in the U.S., there are more than 35,000 
people diagnosed with primary brain tumors. According to Ostrom et al. (2014), gliomas are 
identified to be one of the most common types of brain tumors and are the most common type of 
malignant tumors among younger populations. Gliomas represent 28% of all brain tumors and 
80% of malignant brain tumors. In addition, gliomas account for 53%, 35% and 29% of all brain 
tumors (68%, 74% and 81% of malignant tumors) among children (0-14 years of age), teenagers 
(15-19 years of age) and young adults, respectively.  
There are two main groups of gliomas, low grade gliomas (LGGs) and high grade gliomas 
(HGGs).  LGGs consist of grade I and Grade II gliomas, while Grade III and Grade IV gliomas 
are referred to as HGGs, as defined by the World Health Organization (WHO). Although WHO 
grade I and II gliomas are grouped as LGGs, grade I gliomas can be cured surgically but Grade II 
gliomas remain a challenge for physicians (Pouratian & Schiff, 2010). In this research, we refer 
LGGs to Grade II gliomas.  
Figure 1 shows the age distribution among 280 glioma patients with gray bars for LGG and 
black bars for HGG (Ye, Yang, Geng, Zhou, & Chen, 2002). It is shown from this graph that LGGs 
occur most between the ages of 30 and 39. This matches other reported statistics in the literature. 
For example, in Pallud et al. (2013), the average age of LGG patients at diagnosis, in a sample of 
407 patients, is 39.0 ±  11.0 years. In Schomas et al. (2009), for a patient population of 314 adults, 
the median age at diagnosis is 36 years. In Chaichana et al. (2010), for a patient population of 191, 
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the mean patient age is 34.9 ± 15.3 years. In our study, we assume the ages of the patients to be as 
in the distribution shown in Figure 1. 
 
Figure 1 Age distribution for all glioma patients  (gray: LGG, black: HGG) (YE ET AL., 2002) 
 
There are several review papers on LGGs in the literature in the past few decades  (Recht 
& Bernstein, 1995; Stieber, 2001; Grier, 2006; Sanai, Chang, & Berger, 2011; Forst, Nahed, 
Loeffler, & Batchelor, 2014). These review articles often describe LGGs’ epidemiology, 
prognostic factors, their incidence, current diagnostic methods and treatment and follow-up plans, 
along with some long term risks of recurrence and malignant transformation.   
1.1 Management of Low Grade Gliomas 
Low-grade gliomas (LGGs) are a heterogeneous group of neoplasms more prevalent in younger 
patient populations. LGGs present a unique challenge for patients and physicians as most patients 
will survive a decade or more and may be at a higher risk for treatment-related complications.  The 
management of gliomas includes diagnosis, treatment decisions, and follow-up decisions. 
Although treatment can effectively control the growth of tumors, there is always some amount of 
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residual left after treatment.  Residual tumors are normally progression-free and do no additional 
harm to the patient (Chaichana et al., 2010; Schomas et al., 2009). From clinical studies in recent 
years, some cases of LGGs are identified to manifest more aggressive clinical behaviors, and 
require earlier and more aggressive interventions. As quoted from Dr. Susan Chang from 
University of California at San Francisco “the natural history of low-grade gliomas is that they 
will progress, and over enough time will progress to a higher grade”, we can see that the 
“management of LGGs is one of the most controversial areas in neuro-oncology” (Rees et al., 
2008). The remainder of this section discusses how gliomas are diagnosed and treated (Section 
1.1.1). Recurrence and mortality risks for LGG patients are introduced in Section 1.1.2.  
1.1.1 Diagnosis and treatment 
Gliomas are often diagnosed through radiological imaging and histopathology (Grier, 2006). 
Gliomas are graded under their pathologic evaluation and follow the standards of the World Health 
Organization (WHO). WHO classifies gliomas according to their predominance and grades them 
by the presence or absence of necrosis, mitotic, figures, nuclear atypical, and anthelia cell 
proliferation (Sanai et al., 2011).  
Following diagnosis, there are several treatment options available. The most common 
treatment methods are resection and radiation therapy (McGirt et al., 2008; Recht & Bernstein, 
1995; Stieber, 2001). Gross total resection by opening craniotomy, is the ideal procedure among 
all surgery options for treating LGGs (Sanai et al., 2011; Soffietti et al., 2010; Stieber, 2001).  
While surgery and radiation are still recommended as the first-line treatment of LGGs, 
chemotherapy (CT) is often considered as a second-line treatment. 
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1.1.2 Recurrence and Follow-up 
Although treatment can effectively control the growth of a tumor, there is always residual left after 
treatment.  Residual tumors are normally progression-free and do no additional harm to the patient 
(Chaichana et al., 2010; Schomas et al., 2009). However, there is always a possibility of recurrence 
and malignant transformation. LGGs recur when there is an increment in tumor size. Several 
studies reported the average 5-year recurrence rate as 50-55% (Chaichana et al., 2010; Schomas et 
al., 2009). A recurrent tumor can either have the same properties as the original tumor before the 
first treatment, or transform to a malignant tumor. A progressive LGG can cause highly concerning 
morbidity, and inevitably lead to death (Pouratian & Schiff, 2010). 
Malignant transformation happens when an LGG transforms to have characteristics of an 
HGG. Upon recurrence, tumor can also progress as an LGG first and transform to HGG later.  
Maher et al. (2001) claimed that Grade II tumors are low-grade malignancies that may follow a 
long clinical course but are not curable by surgery. Astrocytoma, a common type of LGG, within 
5-10 years, can transform to Glioblastoma, a type of HGG. In addition, HGG patients are 46 times 
more likely to die than the general population controlling for age, sex and year (Smoll & Hamilton, 
2014). HGG patients usually die due to cerebral edema, a swelling in the brain caused by excessive 
fluid, or increased intracranial pressure (Krex et al., 2007).  
Although the risks of tumor recurrence and malignant degeneration after resection exist, 
there is still no agreement on the estimates for these risks. According to Pignatti (2002), recurrence 
rates and malignant transformation rates seem to correlate with the initial sizes and residual sizes 
of tumors.  Moreover, tumor growth rates inversely correlate with the overall survival (OS) rates 
and progression-free survival (PFS) rates. According to the National Cancer Institute (NCI), OS is 
the length of time the patient is alive since either the date of diagnosis or the start of treatment for 
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a disease. PFS is the “length of time during and after the treatment of a disease that a patient live 
with the disease but it does not get worse”. Table 1 shows some statistics of survival rates for some 
common LGGs. It can be seen that survival rates are highly correlated with patient ages.  
Table 1: The overall survival rate from CBTRUS report 
Histology 
Average age 
at diagnosed 
Relative 2-yr SR 
(%) 
Relative 5-yr SR 
(%) 
Relative 10-yr SR 
(%) 
Pilocytic 17 91.4 87.6 8.3 
Astrocytoma, 
Oligodendroglioma 
42 79.1 64.3 47.0 
Mixed Gliomas 40 73.7 57.7 40.5 
Asrocytoma, NOS 47 34.1 27.2 23.0 
Note: SR = survival rate 
From clinical studies in recent years, some cases of LGGs are identified to manifest more 
aggressive clinical behavior, and require earlier and more aggressive interventions. Figure 2 
(Mainio et al., 2006) shows the probabilities of death from LGGs as compared to HGGs and other 
benign tumors (in a sample size of 101 patients) over a 10-year follow-up period. It can be seen 
that 23.3% of the patients with a benign brain tumor, 63.2 % of the patients with LGG, and 95.5% 
of the patients with HGG died at the end of the follow-up. The mean survival time is 11.6, 9.1 and 
1.9 years for benign brain tumor, LGG, and HGG patients, respectively. Although the survival 
time of LGG patients is relatively long, the majority of these patients still die from gliomas, and 
thus, follow-up decisions can be complicated (Grier, 2006; Maher et al., 2001).  
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Figure 2 Survival Time after Operation (MAINIO ET AL., 2006) 
After surgery, in order to detect recurrence, MRI with contrast enhancement is the gold 
standard to monitor LGGs. MRI can also predict malignant transformation (Soffietti et al., 2010). 
According to Drevelegas and Papanikolaou (2011), sensitivity of MRI appears to be 98% for 
lesions larger than 1cm, and 77% for lesions smaller than 5 mm.  
1.2 Research Objectives 
In this research, we seek to estimate the risks associated with transitions into recurrence, 
malignancy transformation and mortality for LGG patients upon their first successful treatment.  
These risks quantify disease progression as represented by transition probabilities over time. These 
estimates can be incorporated in the development of a natural history model for LGG recurrence 
in future research.  Medical decisions for improving patient outcomes can then be evaluated or 
optimized using the natural history model for a better LGG post-treatment management.  
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 Risk estimation 
In this section, we present the methodologies for risk estimation that quantify LGG recurrence, 
malignancy transformation and mortality over time. We first introduce the disease pathway for 
treated LGG patients (Section 2.1), and then illustrate the methodologies for estimating the risk of 
transitions into each of the states along the pathway (Section 2.2 – 2.5). We denote the risks of 
transitioning to a state at period 𝑡 as the probability of transitioning to the state during time 
𝑡 and 𝑡 + 1.  
2.1 Disease Pathway 
The disease pathway for LGG patients after the first-line of treatment is shown in Figure 3. After 
the first-line of treatment, the patient is considered to be in the progression-free state (State 0), 
which means the tumor is not progressing or expanding. When the tumor starts to grow again, i.e., 
recurrence appears, the patient will move to the tumor recurrence state (State 1). Note that in most 
cases, recurrent LGG tumors grow at the same rate as before the initial treatment (Pallud et al. 
2013). The malignant transformation (State 2) occurs in two cases: (1) the growth rate of the 
recurrent tumor is very high, and (2) the spread of the tumor cells toward other areas of the brain 
is fast (i.e., metastasis occurs). We assume that death from brain tumor (State 3) can only happen 
from a malignant tumor (from State 2). The alive patient may also die from another cause (State 
4) in the next period. Table 2 explains the parameters being estimated in our risk estimation. The 
first column contains the notations while the second column explains their meanings. The third 
column summarizes the sources for risk estimation, and the corresponding subsection for each risk 
estimation is shown in the last column. It should be noted that in this study, all risk estimations 
rely on the information published in the literature. Nevertheless, we have done an extensive 
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literature review to identify the most appropriate sources in order to reduce the bias as much as 
possible.   
 
 
 
Progression 
Free (0)
Tumor 
Recurrence (1)
Malignant 
Transformation 
(2)
Death from 
another Cause 
(4)
Death by Brain 
Tumor (3)
 
Figure 3 Transition between different health states 
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Table 2 Input data sources 
Model parameter description 
Model 
parameter 
Data source Section 
 
- Recurrence from 
progression-free 
- Malignant transformation 
from progression-free 
 
- Malignant transformation 
from recurrence 
 
- Death from brain tumor 
 
- Death from other causes 
Probabilities: 
𝑃01 
 
𝑃02 
 
 
𝑃12 
 
 
𝑃23 
 
𝑃04, 𝑃14, 𝑃24 
 
- Chainacha et al., 20010 
 
- Pallud et al. (2013) 
 
 
- Pallud et al. (2013); Rees et al. (2008) 
 
 
- Schomas et al. (2009) and Davidoff LM, (1940) 
 
- Arias (2010) 
 
- 2.1 
 
- 2.2 
 
 
- 2.3 
 
 
- 2.4 
 
- 2.5 
 
 
 
2.2 Risks of Recurrence from Progression-free (𝑷𝟎𝟏)  
Kaplan Meier survival curves (Kaplan & Meier, 1958) are extensively used in medical studies on 
chronic diseases including brain tumors that follow patients over time with the main goal to 
understand the mortality risk associated with a specific disease or the treatment of such a disease.  
These Kaplan Meier (KM) survival curves are usually derived with large samples that are 
representative of a population. Due to the popularity of KM, we intent to use KM curves as the 
base for the estimation of 𝑃01 and 𝑃02. 
2.2.1 Study Summary 
The probability of a patient transitioning from a progression-free state at time 𝑡 to the tumor 
recurrence state at time 𝑡 + 1 is estimated using published survival curves derived by Chaichana 
et al. (2010) after a 144-month follow-up of 191 patients who had undergone surgery for LGGs at 
a single academic tertiary-care institution. According to Chaichana et al. (2010), the 5- and 8-year 
progression-free survival rates were 44 and 24%, respectively, and the 5- and 8-year malignancy-
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free survival rates were 74 and 56%, respectively. A patient who has not had an LGG recurrence 
from his initial treatment is considered progression-free. Similarly, a living patient without a 
malignant tumor after initial treatment is considered malignant-free. Figures 4A and 4B 
demonstrate the progression-free survival (PFS) and malignant-free survival (MFS) KM curves 
over the course of 144 months from their study. In order to obtain specific data points from this 
figure to estimate risk changes over time (i.e., transition probabilities every six months), we 
reconstruct the figure and use the information from this reconstruction for a curve fitting. The 
results of the curve fitting are then used to calculate the probabilities. 
 
Figure 4 (A) Progression-free survival curve; (B) Malignant-free survival curve (CHAICHANA ET 
AL., 2010) 
 
 
 
2.2.2 Data Reconstruction 
The number of individuals at risk just prior to time t can be seen as the number of individuals in 
the sample who neither died nor were censored prior to time t. Because in the paper (Chaichana et 
al., 2010), no censoring (a form of missing data problem (Guyot, Ades, Ouwens, & Welton, 2012)) 
was presented or mentioned, we assume that the total number censored is zero. The software 
WebPlotDigitizer (Ankit Rohatgi, n.d.) was used to create a list of associated data points from the 
A B 
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curves. The initial number of patients (191) and the ending number of patients by the end of years 
reported in Chaichana et al. (2010) are used for estimation. An event occurs when a patient leaves 
the progression-free survival (PFS) set. The algorithm by Guyot et al. (2012) guides the 
construction of a data set from collected data points. This data contains the number at risk and the 
number of events over time. Some key statistics of the data after applying Guyot et al. ’s algorithm 
are shown in Table 3 and Table 4: 
 
Table 3 Summary of statistic from reconstructed MFS curve 
Initial number 
of patients 
Number 
of events 
Median 
0.95 LCL 
of median 
0.95 UCL 
of median 
191 119 88.7 79.1 99.8 
 
TABLE 4 SUMMARY OF STATISTIC FROM RECONSTRUCTED PFS CURVE 
Initial number 
of patients 
Number 
of events 
Median 
0.95 LCL 
of median 
0.95 UCL 
of median 
191 145 53.3 47.8 74.2 
 
Using the reproduced data, KM curves are graphed, as seen in Figure 5. Comparing the 
shapes between the original graph (Figure 4) and the reconstructed graph (Figure 5B), the 
reconstructed data is deemed close to the original KM curve.  The only additional statistics reported 
in the paper for validation purpose are the median time to recurrence and median time to malignant 
transformation.  We justify the quality of the reconstruction and fitting by comparing our produced 
numbers with these statistics and discuss in detail in Section 2.1.3. 
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Figure 5 Graphs from reconstructed data from CHAICHANA ET AL. (2010) 
 
 
2.2.3 Method of Probability Calculation 
Let 𝑘𝑡 denote the number of patients who are progression-free and alive at time 𝑡, and let 𝑛𝑡 denote 
the number of patients who are malignant-free at time 𝑡 and are alive. If 𝑠 is the total number of 
LGG patients, then the number of patients who either have recurrence, malignant transformation, 
or die at time 𝑡 is 𝑠 − 𝑘𝑡. The number of patients who either have malignant transformation or die 
at time 𝑡 is 𝑠 − 𝑛𝑡.  We assume that patients only die when they reach the malignancy state. 
Therefore, the number of patients with recurrent tumor at time 𝑡 and are alive is 𝑛𝑡 − 𝑘𝑡. In other 
words, the number of patients who experience recurrence at period 𝑡 + 1 and are alive is the 
difference between the malignant-free patients and the number of patients who do not have 
recurrence and survive at period 𝑡 + 1 . Hence, the probability the patient have recurrence for 
period 𝑡 + 1 is assumed to be the number of patients who has recurrence from 𝑡 to 𝑡 + 1 divided 
by the total number of patients who are progression-free at time 𝑡 .  
In order to estimate the risk changes, we further assume a continuous function and apply 
curve fitting to the KM curve. Then, the number of patients that have tumor recurrence at time t is 
calculated using (eq.1), and the number of alive patients at time 𝑡 is computed using (eq.2).  The 
A B 
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summary of the results from the fitting (using (eq.1) and (eq.2)) are shown in Figures 6 and 7, 
respectively.  
The models used to fit the curves resulted with R2 of more than 99% for both functions. Q-
Q plots measure the agreement of a fitted distribution with observed data. The Q-Q plot from 
Figure 6 implies that the models can fit the reconstructed MFS data well, assuming that the 
reconstructed data comes from a continuous and polynomial function. Similar results can be seen 
in Figure 7 for the PFS data. The majority of points lay on the solid line, or stay within the “dotted 
bounds”, which confirms that two data sets (reconstructed data set and fitted data set) in each case 
(PFS and MFS) come from populations with a common distribution. The graphs between the 
reconstructed data and the fitted model (Figures 6A and 7A) do verify that the derived models are 
closed to the reconstructed data distribution. Even though we could not compare the median time 
to recurrence and malignant transformation from the literature, through equations from regressions 
(eq.1) and (eq.2), we were able to find the median of recurrence time to be about 27 months, which 
is relatively closed to the literature (28 months as reported in Chaichana et al. (2010)). 
𝑛𝑡  =   214 − 2.34𝑡 + 4.05 × 10
−2𝑡2 − 4.2 × 10−4𝑡3 + 1.38 × 10−6𝑡4 (eq.1) 
𝑘𝑡  =    203 − 1.76𝑡 − 1.35 × 10
−2𝑡2 + 2.53 × 104𝑡3 − 1.01 × 10−6𝑡4 (eq.2) 
The next goal is to find the probability of tumor recurrence from period  (𝑡 − 1) to 𝑡, which 
is denoted as 𝑝𝑡01. Therefore, the probability an event is occurring during an interval is the sum of 
the probabilities of occurrence during that interval, which gives 𝑝𝑡01, the probability of recurrence 
at period 𝑡, in (eq.3): 
𝑝𝑡01 = {
(𝑛𝑡−𝑛𝑡−1)−(𝑘𝑡−𝑘𝑡−1)
𝑘𝑡−1
             if (𝑛𝑡 − 𝑛𝑡−1) − (𝑘𝑡 − 𝑘𝑡−1) > 0
0                                                                      otherwise.
   (ep.3) 
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Coefficients:   
  Estimate P-value 
(Intercept) 2.14E+02 < 2e-16 
𝑡𝑖𝑚𝑒 -2.34E+00 1.11E-08 
𝑡𝑖𝑚𝑒2 4.05E-02 8.60E-05 
𝑡𝑖𝑚𝑒3 -4.20E-04 9.22E-05 
𝑡𝑖𝑚𝑒4 1.38E-06 0.000249 
𝑅2= 9.92E-01  
 
Figure 6 Fitting Result For Equation (1) 
 
Coefficients:   
  Estimate P-value 
(Intercept) 2.03E+02 < 2e-16 
𝑡𝑖𝑚𝑒 -1.76E+00 9.21E-11 
𝑡𝑖𝑚𝑒2 -1.35E-02 7.22E-02 
𝑡𝑖𝑚𝑒3 2.53E-04 3.89E-03 
𝑡𝑖𝑚𝑒4 -1.01E-06 0.00257 
𝑅2= 9.95E-01   
 
 
 
  
Figure 7 Fitting Result For Equation (2) 
 
0
50
100
150
200
0 24 48 72 96 120 144
N
u
m
b
er
 o
f 
p
at
ie
n
ts
Time (month)
MFS reconstructed MFS fit
0
50
100
150
200
0 24 48 72 96 120 144
N
u
m
b
er
 o
f 
p
at
ie
n
ts
Time (month)
PFS reconstructed Fitted
B A 
B A 
15 
 
2.2.4 Results and Discussion 
The transition probabilities produced from the estimation method in Section 2.1.3 are shown in 
Table 5 for the period of 10 years (120 months). We consider a period to be 6 months. Each 
probability represents the risk of recurrence in the corresponding period for a progression-free 
patient.  
Table 5 Recurrence Probabilities over Time 
Time (month) P(recurrence) Time (month) P(recurrence) 
6 0.078813535 66 0.050190744 
12 0.056518543 72 0.043082856 
18 0.042414754 78 0.029172641 
24 0.034996228 84 0.008009822 
30 0.032873925 90 0.000000000 
36 0.034685739 96 0.000000000 
42 0.039026483 102 0.000000000 
48 0.044398714 108 0.000000000 
54 0.049191115 114 0.000000000 
60 0.051696998 120 0.000000000 
 
The initial transition probability at 6-month is high (0.0788) while it keeps reducing for 48 
months (4 years) and, then goes back up to 0.05. For the time between the 60th month (5th year) 
and the 78th month (6.5th year) periods, the probabilities decrease again. From the 84th month (7th 
year) to the 90th month (7.5th year), there is mostly no risk of recurrence. These behaviors can be 
observed from Figure 5, whereas from the 84th month to the 100th month, the slope of PFS is not 
as steep as MFS. Then, from the 100th month to the 120th month, all the progress-free patients stay 
in the PFS group. In other words, after 90 months (7 years) till the end of 120 months (10 years), 
since the tumor is more likely to become malignant and no recurrence is observed during this 
period based on the survival curves, the transition probabilities are zero. 
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2.3 Risks of Malignant Transformation from Progression-free (𝑷𝟎𝟐) 
2.3.1 Study Summary 
We applied a similar approach as described in Section 2.1, using reconstructed data derived from 
Pallud et al. (2013)’s published KM curves to estimate the probability of malignant transformation 
from progression-free. From Pallud et al., by the end of the follow-up, 209 patients had malignant 
transformation, and 87 patients died of brain tumor progression (from either recurrent tumor or 
malignant tumor). No censoring is also assumed as no such information is reported in the paper. 
Figure 8 presents the KM curves of the overall survival (8A) and the general malignant-free 
survival (8B).  
 
 
Figure 8 KM estimates of OS and malignant progression-free survival according to velocity of 
diametric expansion (Pallud et al., 2013). 
 
 
2.3.2 Data Reconstruction 
Using the same approach presented in Section 2.1.2, we reconstruct the data using the algorithm 
by Guyot et al. Figure 9 displays the graph of the reconstructed data. Moreover, the median of the 
A B 
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reconstructed MFS curve is 90.8 months, and the median from the original curve is 103; this error 
may come from the no censoring assumption. The median from the reconstructed OS curve is 248, 
and the median from the original curve is 249 months. The shapes of the reconstructed curve are 
closed to the shape of the original KM curve.  
 
 
 
 
   
 
Figure 9 Reconstructed KM curves from Pallud et al. 
 
2.3.3 Method of Probability Calculations 
Using a similar analysis as in Section 2.1.3, the probability a patient moves to the malignant 
transformation state is the fraction of the number of patients who survive and have malignancy at 
time t and the total number of patients who did not have malignant tumor at time 𝑡 − 1. Similarly, 
a continuous curve fitting is applied for ease of calculations. The same validation procedure as in 
Section 2.1.3 verifies that the models in (eq.4) and (eq.5) represent our reconstructed data well. 
The Q-Q plots from Figure 10 and Figure 11 implies that our models can implement with our 
reconstructed data, assuming that the reconstructed data are continuous. In both MFS and OS 
cases, exponential functions are fitted. The first order of the OS function was discarded because 
the p-value of the coefficient is not significant (p=0.957).   
A B 
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In this section, 𝑚𝑡, 𝑙𝑡 are denoted as the number of malignant-free patients at time t and the 
number of alive patient at time t, correspondingly. From fitting the curves, we derive (eq.4) and 
(eq.5). The probability of malignant transformation during time (𝑡 − 1) and 𝑡 can be calculated 
through (eq.6), which is similar to (eq.3). 
𝑚𝑡 = Exp [6.077 −
2.562𝑡
103
−
3.837𝑡2
106
]       (eq.4) 
𝑙𝑡 = Exp [6.12 −
9𝑡
103
+
1.89𝑡3
107
−
8.941𝑡4
1010
]   (eq.5) 
The next goal is to find the probability of tumor malignant transformation from progression 
from period  (𝑡 − 1) to 𝑡, which is denoted as 𝑝𝑡02. The probability is calculated as in (eq.6). 
Similarly, the probability an event is occurring during an interval is the sum of the probabilities of 
occurrence during that interval, which gives: 
𝑝𝑡02 = {
(𝑚𝑡−𝑚𝑡−1)−(𝑙𝑡−𝑙𝑡−1)
𝑙𝑡−1
             if (𝑚𝑡 −𝑚𝑡−1) − (𝑙𝑡 − 𝑙𝑡−1) > 0
0                                                                      otherwise
 (eq.6) 
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Coefficient Estimate P-value 
𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 6.077 <2E-16 
𝑡𝑖𝑚𝑒 -2.56E-03 <2E-16 
𝑡𝑖𝑚𝑒2 -3.84E-06 4.47E-07 
   
𝑅2= 0.9901   
 
Figure 10 Fitting OS for malignant data 
Coefficient Estimate P-value 
𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 6.12 <2E-16 
𝑡𝑖𝑚𝑒 -9.57E-03 <2E-16 
𝑡𝑖𝑚𝑒3 1.90E-07 5.29E-09 
𝑡𝑖𝑚𝑒4 -8.91E-10 <2E-16 
   
𝑅2= 0.9948   
 
Figure 11 Fitting MFS Probability of malignant transformation from recurrence 
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2.3.4 Results and Discussion 
The transition probabilities produced from the estimation method are shown in Table 6 for the 
period of 10 years (120 months). 
 
Table 6 Malignant transformation probabilities over time 
Time 
(month) 
P(malignant) 
Time 
(month) 
P(malignant) 
6 0.037786384 66 0.020348917 
12 0.036718447 72 0.018320041 
18 0.035422169 78 0.016355913 
24 0.033926502 84 0.014484168 
30 0.032260659 90 0.012731505 
36 0.03045409 96 0.011123485 
42 0.028536426 102 0.00968433 
48 0.026537404 108 0.008436708 
54 0.024486769 114 0.0074015 
60 0.022414148 120 0.006597547 
  
As can be seen in the results from Table 6 above, the initial transition probability between 0 
and 6 months is the highest (0.037786). The probabilities keep decreasing and at 120th month (10th 
year), the probability is 0.0065975. Comparing with the results from the probability of recurrence 
from progression-free, the probabilities are smaller up to 90th month (7th year). The probabilities 
of malignant transformation after 7th year are greater than the probabilities of recurrence (𝑃01). 
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2.4 Risks of Malignant Transformation from Recurrence (𝑷𝟏𝟐) 
2.4.1 Summary of Methods 
According to Rees et al. (2008),  the rate of malignant transformation highly depends on the size 
of the tumor’s volume. Moreover, Pallud et al. (2013) believe that the diametric expansion rate of 
recurrence is a reliable predictor of early malignant transformation for LGGs. In summary, there 
are two factors we need to use in order to find the tumor volume, which determine the risks of 
malignant transformation: 1) the residual of the tumor after the first line of treatment, and 2) the 
growth rate of the recurrent tumor. Using Pallud et al. (2013)’s tumor growth distribution, we can 
calculate the volume of the patient’s recurrent tumor over time, given that the growth rate remains 
static. Using the risk prediction from Rees et al. (2009), the probability of malignant transformation 
can be estimated.   
2.4.2 Obtaining the Volume of Recurrent Tumor 
The risk of malignant transformation is dependent on the volume of the tumor at time 𝑡. In this 
section, we focus on determining the tumor volume through the growth rate of the recurrent tumor. 
Even though the tumor shapes are not the same in every patient, previous studies, such as Pallud 
et al. (2013) and Rees et al. (2009), have simplified the growth through diametric expansion rate. 
The distribution of velocities of diametric expansion rate from 407 LGG patients (Pallud et al. 
2013) (Figure 12) is used to estimate the probability of volume growth during a period when 
recurrence occurs.  
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Figure 12 Distribution of the 407 patients by individual velocities of diametric expansion 
(PALLUD ET AL., 2013) 
 
Following Pallud et al. (2013) and Rees et al. (2008), tumors are assumed to be spherical 
to simplify the volume calculation. Denote 𝑉𝑡 (cm
3 or ml) as the tumor volume at time t and the 
growth rate of the tumor is 𝑣𝐿 (cm/yr). Assuming that the initial diameter of the residual tumor 
after the first line of treatment is 𝑑𝑖 (cm), the time (year) the tumor has recurred and the diametric 
expansion rate of the recurrent tumor are known, we can calculate the tumor volume at time t as 
in eq.7:  
  𝑉𝑡 =
4𝜋(
𝑑𝑖
2
+
𝑡 𝑣𝐿
2
)
3
3
  (eq.7) 
2.4.3 Risk of Malignant Transformation 
As previously mentioned, the risk of malignant transformation is significantly dependent on tumor 
volume. According to Rees et al. (2009), tumor volumes and growth rates were calculated using 
semi-automated segmentation, and analyzed in a hierarchical regression model among twenty-
seven patients with biopsy-proven, untreated LGGs who had at least three MRI studies at 6 month 
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intervals. It is reported that for every 10% increment in tumor volume, after adjustment, risk of 
transformation increases by 29% with 95% Confidence Interval (CI) of 10-51%. Comparing the 
probability of malignant transformation for tumor volume size 𝑉1 and 𝑉2 (i.e., 𝑟1 versus 𝑟2), we 
have 
r2 = 𝑟1 × 1.29,   if 𝑉2 = 𝑉1 × 1.1. 
Then, considering number of increments using 𝑛, we have: 
 𝑟2 = 𝑟1 × 1.29
𝑛,  if 𝑉2 = 𝑉1 × 1.1
𝑛. 
Therefore, 
 
V2
V1
= 1.1𝑛  and  
𝑟2
𝑟1
= 1.29𝑛, (eq.8) 
log1.1 (
V2
V1
) = log1.29 (
𝑟2
𝑟1
) .  
𝑟2 = 𝑟1 × 1.29
log1.1(
𝑉2
𝑉1
)
 (eq.9) 
Given that after the initial treatment the initial residual radius is 0.75cm and the diametric 
expansion is 4.5cm/yr, the maximum tumor volume is 27.6116ml and 113.097ml within 6 months 
and 12 months, respectively (obtained from (eq.7)). Table 7 shows the base values we use to 
calculate the risks of malignant transformations. In Table 7, because we have multiple volume 
values and multiple risk values, but the number of volume values are not enough to fit an equation,  
it is best to weight the values when calculating the risks. The difference between two reported 
volumes in Table 7 is 20ml, therefore the risks are calculated as in equation 10 with the volume 
values, associating with its risks, shown in Table 7. When applying equation 9 with the volumes 
in Table 7 to compare our results with reported values from Table 7, the errors obtained are shown 
in Table 8. These errors are within the 95% CI, which are between 10-51%. Because the errors are 
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within the 95% CI, equation 9, based on information provided from Rees et al. (2008) is okay to 
use.   
Table 7 Reported tumor volume with its associated risks (REES ET AL., 2008) 
 
Tumor Volume (ml) , 𝑉1 
Risk at 6 
moths (%) 
Risk at 12 
months (%) 
𝑉1𝑎 60 6 12 
𝑉1𝑏 80 14 34 
𝑉1𝑐 100 25 50 
𝑉1𝑑 120 38 65 
𝑉1𝑒   140 53 77 
𝑉1𝑓 160 67 87 
 
𝑟2 =
{
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 𝑟1𝑎 × 1.29
log1.1(
𝑉2
𝑉1𝑎
)
,     if V2 < 𝑉1𝑎
(1 −
𝑉2−𝑉1𝑎
20
) (𝑟1𝑎 × 1.29
log1.1(
𝑉2
𝑉1𝑎
)
) + (
𝑉2−𝑉1𝑎
20
) (𝑟1𝑏 × 1.29
log1.1(
𝑉2
𝑉1𝑏
)
) , if V2 ∈ [𝑉1𝑎 , 𝑉1𝑏)
(1 −
𝑉2−𝑉1𝑏
20
) (𝑟1𝑏 × 1.29
log1.1(
𝑉2
𝑉1𝑏
)
) + (
𝑉2−𝑉1𝑏
20
) (𝑟1𝑐 × 1.29
log1.1(
𝑉2
𝑉1𝑐
)
) , if V2 ∈ [𝑉1𝑏 , 𝑉1𝑐)
(1 −
𝑉2−𝑉1𝑐
20
) (𝑟1𝑐 × 1.29
log1.1(
𝑉2
𝑉1𝑐
)
) + (
𝑉2−𝑉1𝑐
20
) (𝑟1𝑑 × 1.29
log1.1(
𝑉2
𝑉1𝑑
)
) , if V2 ∈ [𝑉1𝑐 , 𝑉1𝑑)
(1 −
𝑉2−𝑉1𝑑
20
) (𝑟1𝑑 × 1.29
log1.1(
𝑉2
𝑉1𝑑
)
) + (
𝑉2−𝑉1𝑑
20
) (𝑟1𝑒 × 1.29
log1.1(
𝑉2
𝑉1𝑒
)
) , if V2 ∈ [𝑉1𝑑 , 𝑉1𝑒)
(1 −
𝑉2−𝑉1𝑒
20
) (𝑟1𝑒 × 1.29
log1.1(
𝑉2
𝑉1𝑒
)
) + (
𝑉2−𝑉1𝑒
20
)(𝑟1𝑓 × 1.29
log1.1(
𝑉2
𝑉1𝑓
)
) , if V2 ∈ [V1e, V1f)
𝑟1𝑓 × 1.29
log1.1(
𝑉2
𝑉1𝑓
)
,     if V2 > 𝑉1𝑓
   (eq.10) 
 
Table 8 Errors from using equation 8 
Error %, 
6 months 
Error %, 
12 
months 
10.23822 37.37406 
2.743955 33.48565 
14.04235 37.33991 
19.2163 49.07868 
34.29712 47.90856 
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  Finally, using the distribution of growth rate from Pallud et al. (2013) in Figure 12 above, 
we can calculate the expected risk of malignant transformation. Given 𝑛𝑖, the number of patients 
who has growth rate 𝑖 (𝑖 = 1…45 𝑚𝑚/𝑦𝑟), and 𝑟𝑖, the probability of transformation for that 
growth rate, the weighted probability conditioning on the growth rate of malignant transformation 
is: 
𝑃 = ∑ (𝑃𝑖|𝑑𝑖) × 𝑑𝑖
45
𝑖=1  (eq.10) 
 
2.4.4 Results and Discussion 
The probability of malignant transformation is dependent on the growth rate of the tumor. The 
results for different growth rates are shown below in Figure 13 for the initial tumor radius of 
0.75cm and an initial tumor radius of 1cm. To illustrate our calculations, some examples are 
provided.  
If the residual tumor’s radius is 0.75cm, and the diametric expansion is 4.5mm every 6 
months, then in 6 months, from (eq.6) the volume is 𝑉𝑡 = (
4𝜋
3
) (0.75 +
0.45
2
)
3
= 2.6876 𝑐𝑚3. 
Using the values from Table 7 as base values to estimate the transition probability from recurrence 
to malignant transformation, we can apply eq.8 to find the risk of malignant transformation 𝑟2. If 
at recurrence, the growth rate of the patient is 4.5mm/yr, from the initial diameter of 1𝑐𝑚, the 
volume of tumor after 6 months will be 𝑉2 =  1.596𝑚𝑙. We know that 𝑟1 = 6% at tumor volume 
of 𝑉1 = 60𝑚𝑙. Applying eq. 8, we have:  
𝑟2 = 𝑟1 × 1.29
log1.1(
𝑉2
𝑉1
)
⇔ 6× 1.29log1.1(
2.6876
60 ) = r2 = 0.001494% 
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The results in Figure 13 shows the results of transformation risks from a recurring tumor 
based upon the time, the initial tumor radius and the growth rate. This results show how the growth 
significantly affects the risk of transformation. Numerical results are shown in Appendix 1.  
 
  
Figure 13 Risk of malignant transformation from recurrence tumor 
 
 
2.5 Risks of Death from other Causes  
(𝑷𝟎𝟒 = 𝑷𝟏𝟒 = 𝑷𝟐𝟒) 
A summary of how death from other causes are obtained is shown in Table 9. Using the CDC Life 
tables (http://wonder.cdc.gov/ucd-icd10.html), we are able to obtain the risks of death from all 
causes (second column) and the risks of death from all CNS neoplasms. The maximal amount of 
diagnosed gliomas a year is 80% of all CNS cases. The third column in Table 9 shows 80% of 
deaths from CNS neoplasms. Taking the difference between the total death from all causes and 
80% of death from CNS, we have the estimated risks of death from other causes. The age groups 
are picked based upon the range of age of LGG patients at diagnosis reported in Section 1.   
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Table 9 Risks of death from other causes 
Ages Percentage of death from all causes Death from CNS neoplasms 80% of CNS Death from other causes 
15-24 0.07400% 0.00000798% 6.38136E-08 0.07399% 
25-34 0.10520% 0.00000740% 5.92387E-08 0.10519% 
35-44 0.18700% 0.00000935% 7.48233E-08 0.18699% 
45-54 0.41900% 0.00001641% 1.31292E-07 0.41899% 
 
2.6 Probability of Death from Tumor (𝑷𝟐𝟑) 
2.6.1 Methods of Calculation 
A small record was found from Davidoff M.L. (1940), which discloses duration of life, in years, 
calculated from the first time gliomas were removed during 1925-1926. Radiation therapy was not 
widely applied toward tumor treatment until 1950s (Dept. of Radiation Medicine, n.d.). Therefore, 
we can assume that the deaths since initial surgery reported in Davidoff’s table (Table 10) are 
natural deaths without any interventions. However, such a small sample of data does not guarantee 
accuracy. In other words, the sample size of Davidoff’s data is small, only 48 patients, after deaths 
from surgery are taken out. Due to a small sample size, it is hard to justify if the probabilities of 
natural death after 2 or 3 years, calculated from Davidoff’s data, is good. Therefore, we used the 
current the OS curve, reported from the literature to find the probabilities of natural death from 
tumor, after we have compared the difference between Davidoff’s data versus our current OS data. 
We cannot use OS curve alone to estimate the probabilities of natural death because the reported 
OS data from recent studies may include patients with treatment while being alive. Therefore, we 
use the OS reconstructed data from Schomas et al. (2009) to assist with finding the probability of 
natural death from Gliomas. 
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The probability of death from Gliomas at time 𝑡 for LGG patients is the ratio of the patients 
who died within time 𝑡 and 𝑡 + 1 and the number of living patients at 𝑡. Eq. 11 expresses this 
formula, where 𝑛𝑡 is the number of living patients at time 𝑡: 
 
𝑃23 =
𝑛𝑡−𝑛𝑡+1
𝑛𝑡
 (eq.11) 
 
We found that the probability of death within 1 year after treatment of LGG from Schomas 
et al. is  
314−292
314
= 0.070064, and the same probability from Davidoff is 
15
62−14
= 0.3125. We see 
that the ratio between the two probabilities for the first year is 
0.3125
0.070064
= 4.46. This means the 
chance of death from having no clinical intervention is 4.46 times higher than having clinical 
adjuvant treatment within the first year after the initial treatment. The probability of death between 
the first and the second year from Schomas et al. is 
292−267
292
= 0.085616. The same probability 
from Davidoff M.L. is 
4
62−14−15
= 0.12121. We see that the ratio between the two probabilities 
for the second year is 
0.12121
0.085616
= 1.42. Similarly, we calculated the ratios of the probabilities using 
statistics reported from Schomas et al. and Davidoff, and obtained the Table 11. The ratios of the 
first year is high (4.46) while the ratios from the 2nd to the 5th years remain less than 2.25. The 
average of the ratios is 2.15. We only consider the values of the first 4 years in Davidoff M.L.’s 
report because the total number of alive patients dropped significantly at the 5th year compare to 
the 1st year (62 − 14 − 15 − 4 − 6 − 4 − 3 =19). A sample size less than 20 is not a good sample 
size for estimates. For this study, we use the average to calculate the risks of death.  
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Table 10 Gliomas Occurring During 1925-1926: duration of life, in years, (Davidoff M.L., 1940)  
Type Total\time 
Death 
at 
surgery 
0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 
Oligodendroglioma 3.00 1.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 
Cyst only 5.00 0.00 2.00 0.00 1.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 
Astroblastoma 6.00 1.00 0.00 0.00 1.00 1.00 0.00 2.00 0.00 0.00 0.00 0.00 
Ependymoma 3.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Spogioblastoma 4.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Papilloma 2.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Astrocytoma 19.00 5.00 3.00 2.00 1.00 2.00 0.00 0.00 0.00 0.00 0.00 1.00 
Glioblastoma Multiform 12.00 2.00 6.00 0.00 3.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 
Medulloblastoma 5.00 2.00 2.00 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00 
Atypical Gliomas 3.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Total 62.00 14.00 15.00 4.00 6.00 4.00 3.00 3.00 0.00 0.00 0.00 1.00 
 
 
 
Table 11 Probabilities comparison between Davidoff M.L. and Schomas's published results 
Year 
Probability of 
death from 
Davidoff M.L's 
Probability of 
death from 
Schomas's 
Ratio 
1.00 0.3125 0.0701 4.46 
2.00 0.1212 0.0856 1.42 
3.00 0.2069 0.0933 2.22 
4.00 0.1739 0.1120 1.55 
5.00 0.1579 0.1402 1.13 
  
Average of the 
ratios= 
2.15 
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2.6.2 Results and Discussion 
The probability of death from tumor is shown in Table 12  
Table 12 Probabilities of death from recurrence tumor 
Time (month) 
Probability of death 
from tumor 
Time (month) 
Probability of death 
from tumor 
6 0.047929936 66 0.184946237 
12 0.10504886 72 0.139117647 
18 0.103082192 78 0.094654088 
24 0.077338129 84 0.11025641 
30 0.120335821 90 0.101689189 
36 0.084980237 96 0.106737589 
42 0.089211618 102 0.096268657 
48 0.158225108 108 0.10078125 
54 0.150700935 114 0.105737705 
60 0.140452261 120 0.092672414 
 
From Table 12, we see that the probability of death between 12th month and 42th month 
and between 78th month and 120th month for 6-month intervals with recurrence tumors stays about 
0.1 . The risk of death from malignant transformation increases if there is recurrence between the 
48th month (4th year) and 72th month (6th year).   
In this study, we have assumed that malignant patients are patients with tumor transforming 
to grades III and IV gliomas. When we compare our probability of death from our results with 
probabilities of death from published papers in HGG there were significant differences. Through 
reconstructing Silverstein et al. (1996) data, the probability of dying from Grade IV Gliomas with 
treatment within 6 months is 0.3125 and the probability of death within 1 year is 0.59375. It 
seemed that our probabilities have remained low to include only the patients who have big tumors 
but were not highly diffusive, more likely to be Grade III Gliomas. As seen in Figure 14 below, 
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the survival curve of Grade IV Gliomas (age < 65)’s curve is a lot steeper compared to the Grade 
III Gliomas (age < 65)’s curve. 
 
Figure 14 Survival, stratified by grade of astrocytoma and age of patients  (Silverstein et al., 
1996) 
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 Conclusion and Future Work 
This research illustrates the methodologies to calculate risks of recurring LGGs using published 
statistics from the literature. We selected the most related studies and used their results to apply 
toward our methods. For the probabilities of recurrence and malignant transformation from 
progression-free, we exploited published progression-free survival, malignant-free survival and 
overall survival curves. We recreated the curves and applied equation fittings in order to find the 
probabilities. Probabilities of death from tumor and death from other causes are estimated from 
deaths statistics reported.  
There are several limitations in this research, which needs to be justified. Firstly, by 
assuming censoring is zero for the survival curves, the median of the reconstructed data for MFS 
is different (90 months versus 103 months). Secondly, although we tried to validate the results, for 
some parameters, there is no additional study that may enable validation. Thirdly, in order to 
simplify our risk model, we assumed that malignant patients are patients Grade III and Grade IV 
tumors. However, when we compare our probability of death from our results with probabilities 
of death from published papers in HGG there were significant differences. Our probabilities have 
remained low to include the patients who have big tumors but were not highly diffusive. In the 
future work, we would like to separate tumor into specific malignant types, such that tumors with 
fast growth, diffusive tumors and tumor which have both characteristics would be considered in 
order to make the mortality risks more realistic. Fourthly, in our study, we assumed that patients 
only die from the tumors are big or from tumors that are highly diffusive. In reality, patients can 
also die from small tumors, but only when the tumors create side effects, such as seizure, blindness, 
or immobility.   
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 To the best of our knowledge, this is the first study that models all possible risks for 
different time intervals of recurrent LGGs, despite of the long term risks and the popularity of 
LGG among CNS tumor patients. The results of this work may have an important contribution 
toward medical decision making community, such that it can be developed toward a natural history 
model and be applied toward other models for cost-effectiveness, decision models on follow-up 
schedules, or decisions models on treatment time. Moreover, methodologies illustrated in this 
research can be applied toward studies of diseases whose data is not readily available or studies of 
diseases in the past, whose statistical reports are limited. In the future, we would like to add more 
states in our model. High grade tumors should be divided into “fast growth” group, “diffusive” 
group, and “fast growth and diffusive” group. A partially observable Markov chain can be formed 
and it will apply some of the results found in this study in order to evaluate different follow-up 
policies for recurring LGGs. Although validation of the proposed methods is difficult given limited 
literature on LGG, we seek to apply our methods to other chronic diseases that have more research 
on natural history modeling, e.g., breast cancer, for validation purposes. 
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Appendix 
Numerical results of malignant transformation from recurring tumor. 
  Initial radius= 0.75cm Initial Radius=1cm 
Growth Rate/12 month Distribution 6 month risk % 12 month risk % 6 month risk % 12 month risk % 
0.10 0.098280098 0.000634177 0.001635892 0.005962504 0.014465718 
0.20 0.154791155 0.000817948 0.002659411 0.007232873 0.021002618 
0.30 0.144963145 0.001046743 0.00420485 0.008734119 0.029992136 
0.40 0.113022113 0.001329708 0.006485678 0.01050133 0.042184695 
0.50 0.088452088 0.001677491 0.009783726 0.012573928 0.058513203 
0.60 0.152334152 0.002102429 0.014465718 0.014996098 0.080126998 
0.70 0.054054054 0.00261876 0.021002618 0.017817226 0.108430319 
0.80 0.024570025 0.003242845 0.029992136 0.021092389 0.145125712 
0.90 0.01965602 0.003993423 0.042184695 0.02488286 0.192262765 
1.00 0.014742015 0.004891873 0.058513203 0.02925666 0.252292588 
1.10 0.00982801 0.005962504 0.080126998 0.034289134 0.328128488 
1.20 0.007371007 0.007232873 0.108430319 0.040063578 0.423213282 
1.30 0.007371007 0.008734119 0.145125712 0.046671889 0.541593724 
1.40 0.012285012 0.01050133 0.192262765 0.054215267 0.688002526 
1.50 0.007371007 0.012573928 0.252292588 0.062804949 0.867948473 
1.60 0.00982801 0.014996098 0.328128488 0.072563 1.087815167 
1.70 0.007371007 0.017817226 0.423213282 0.083623129 1.354968901 
1.80 0.00982801 0.021092389 0.541593724 0.096131573 1.677876252 
1.90 0.00982801 0.02488286 0.688002526 0.110248012 2.066231927 
2.00 0.007371007 0.02925666 0.867948473 0.126146544 2.531097463 
2.10 0.007371007 0.034289134 1.087815167 0.14401671 3.085051376 
2.20 0.004914005 0.040063578 1.354968901 0.164064569 3.742351368 
2.30 0.004914005 0.046671889 1.677876252 0.186513833 4.519109228 
2.40 0.004914005 0.054215267 2.066231927 0.21160706 5.433479082 
2.50 0.002457002 0.062804949 2.531097463 0.239606897 6.505859635 
2.60 0 0.072563 3.085051376 0.270797398 7.759111107 
2.70 0.002457002 0.083623129 3.742351368 0.305485396 9.218787547 
2.80 0.002457002 0.096131573 4.519109228 0.344001943 10.91338524 
2.90 0 0.110248012 5.433479082 0.386703816 13.19788528 
3.00 0 0.126146544 6.505859635 0.433975095 16.4316289 
3.10 0.002457002 0.14401671 7.759111107 0.486228809 20.37284026 
3.20 0 0.164064569 9.218787547 0.543908659 25.15833328 
3.30 0.002457002 0.186513833 10.91338524 0.607490816 30.94801962 
3.40 0.004914005 0.21160706 13.19788528 0.677485791 35.99494708 
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Appendix (cont.) 
  Initial radius= 0.75cm Initial Radius=1cm 
 
Growth Rate/12 
month 
Distribution 6 month risk 
% 
12 month risk 
% 
6 month risk 
% 
12 month risk 
% 
3.60 0 0.270797398 20.37284026 0.838939786 43.72700484 
3.70 0.002457002 0.305485396 25.15833328 0.931609563 47.68655483 
3.80 0 0.344001943 30.94801962 1.033118008 51.78734865 
3.90 0 0.386703816 35.99494708 1.144178364 56.10737619 
4.00 0 0.433975095 39.80730408 1.265551236 60.31050621 
4.10 0 0.486228809 43.72700484 1.39804707 64.26504064 
4.20 0.002457002 0.543908659 47.68655483 1.54252874 68.44331307 
4.30 0 0.607490816 51.78734865 1.699914223 72.39011199 
4.40 0 0.677485791 56.10737619 1.871179386 75.78364276 
4.50 0 0.754440398 60.31050621 2.05736087 79.4203307 
      
Weighted value= 0.008744626 0.429930525 0.03630759 0.991013351 
 
  
